Publications by authors named "G W Van Imhoff"
Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study.
Front Immunol
September 2024
Introduction: There are no reports in LATAM related to longitudinal humoral and cellular response to adenovirus based COVID-19 vaccines in people with Multiple Sclerosis (pwMS) under different disease modifying therapies (DMTs) and neutralization of the Omicron and Wuhan variants of SARS-COV-2.
Methods: IgG anti- SARS-COV-2 spike titer were measured in a cohort of 101 pwMS under fingolimod, dimethyl fumarate, cladribine and antiCD20, as well as 28 healthy controls (HC) were measured 6 weeks after vaccination with 2 dose (Sputnik V or AZD1222) and 3 dose (homologous or heterologous schedule). Neutralizing capacity was against Omicron (BA.
Background: Patients with newly diagnosed high-risk Burkitt lymphoma are treated with high-intensity immune-chemotherapy regimens such as R-CODOX-M/R-IVAC or with lower-intensity regimens such as DA-EPOCH-R. The aim of this study was to make a formal comparison between these regimens.
Methods: This multicentre, phase 3, open-label, randomised study was done in 26 clinical centres in the Netherlands, Belgium, and Switzerland.
Article Synopsis
- A large cohort study involving 4,919 Hodgkin lymphoma (HL) patients treated before age 51 revealed significant long-term mortality risks and treatment-related morbidity, with a notable 5.1-fold increase in deaths from non-HL causes.
- After 40 years, HL survivors had a cumulative mortality rate from non-HL causes similar to that of average 71-year-olds in the general population, indicating a major health concern for long-term survivors.
- The study highlighted that while treatments from 1989-2000 resulted in lower cardiovascular disease mortality compared to earlier periods, specific treatment approaches, like chemotherapy alone for stage I-II, showed higher HL mortality but lower overall mortality from other causes compared to radiation treatments.
Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) as compared to patients without MYC rearrangement. Although intensive chemotherapy regimens yield higher remission rates, toxicity remains a concern. Lenalidomide is an oral immunomodulatory drug which downregulates MYC and its target genes thereby providing support using lenalidomide as additional therapeutic option for MYC+ LBCL.
View Article and Find Full Text PDFPTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61-80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37.
View Article and Find Full Text PDF